Ignite Creation Date:
2025-12-24 @ 11:36 PM
Ignite Modification Date:
2026-02-22 @ 7:02 AM
Study NCT ID:
NCT02358356
Status:
COMPLETED
Last Update Posted:
2022-07-05
First Post:
2014-11-04
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study
Sponsor:
Australasian Gastro-Intestinal Trials Group
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-11
Start Date Type:
None
Primary Completion Date:
2021-10-31
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-10-31
Completion Date Type:
ACTUAL
First Submit Date:
2014-11-04
First Submit QC Date:
None
Study First Post Date:
2015-02-09
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-07-01
Last Update Post Date:
2022-07-05
Last Update Post Date Type:
ACTUAL